Arrowhead Pharmaceuticals, Inc. Share Price
Stocks
ARWR
US04280A1007
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.72 USD | +2.88% |
|
+2.45% | +10.97% |
| 30/06 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Index | CI |
| 29/06 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark | CI |
| Market Cap | 1.01TCr 884.6Cr 819.64Cr 754.41Cr 1.42TCr 97TCr 1.44TCr 9.78TCr 3.83TCr 48TCr 3.79TCr 3.71TCr 1,64500Cr | P/E 2026 * |
-22.2x | P/E 2027 * | -16.5x |
|---|---|---|---|---|---|
| Enterprise Value | 912.1Cr 799.46Cr 740.75Cr 681.79Cr 1.29TCr 88TCr 1.3TCr 8.84TCr 3.46TCr 43TCr 3.42TCr 3.35TCr 1,48600Cr | EV / Sales 2026 * |
20.6x | EV / Sales 2027 * | 28.4x |
| Free-Float |
94.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Arrowhead Pharmaceuticals, Inc.
| 1 day | +2.89% | ||
| 1 week | +2.45% | ||
| Current month | -9.62% | ||
| 1 month | -10.16% | ||
| 3 months | +3.69% | ||
| 6 months | +8.98% | ||
| Current year | +10.97% |
| 1 week | 69.88 |  | 75.06 |
| 1 month | 69.88 | | 87.83 |
| Current year | 54.02 | | 87.83 |
| 1 year | 14.3 | | 87.83 |
| 3 years | 9.57 | | 87.83 |
| 5 years | 9.57 | | 87.83 |
| 10 years | 1.2 | | 93.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/12/2007 | |
Daniel Apel
DFI | Director of Finance/CFO | - | 13/05/2025 |
Peter Carignan
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | - | |
Mauro Ferrari
BRD | Director/Board Member | 66 | 19/08/2010 |
Michael Perry
BRD | Director/Board Member | 66 | 19/12/2011 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 15/06/26 | Free | Director | 11,882 | 0.0084% | ||
| 15/06/26 | Other | Director | 0 | 0% | ||
| 12/05/26 | Sell | Director | -2,970 | 0.0021% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.88% | +2.45% | +400.82% | +104.19% | 1.01TCr | |
| +0.88% | -0.13% | +57.39% | +54.58% | 5.38TCr | |
| +1.80% | +5.16% | +53.09% | +86.95% | 5.47TCr | |
| +0.29% | -2.60% | +4.34% | +408.75% | 2.32TCr | |
| +0.59% | +2.58% | -14.85% | -14.60% | 2.33TCr | |
| +1.46% | +4.02% | +35.97% | -4.03% | 2TCr | |
| +0.30% | -0.40% | +33.13% | -33.46% | 1.73TCr | |
| 0.00% | -6.00% | +163.95% | +284.69% | 1.5TCr | |
| +1.49% | +1.49% | +31.63% | +654.98% | 1.54TCr | |
| +0.51% | +0.09% | +26.12% | +183.49% | 1.4TCr | |
| Average | +1.01% | -1.99% | +79.16% | +172.55% | 2.47TCr | |
| Weighted average by Cap. | +1.04% | -1.85% | +58.34% | +138.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 44Cr 39Cr 36Cr 33Cr 62Cr 4.26TCr 63Cr 428.75Cr 167.78Cr 2.09TCr 166.04Cr 162.47Cr 7.21TCr | 32Cr 28Cr 26Cr 24Cr 46Cr 3.13TCr 46Cr 314.52Cr 123.08Cr 1.53TCr 121.81Cr 119.19Cr 5.29TCr |
| Net income | -46Cr -40Cr -37Cr -34Cr -65Cr -4.42TCr -65Cr -444.37Cr -173.89Cr -2.16TCr -172.09Cr -168.39Cr -7.47TCr | -63Cr -55Cr -51Cr -47Cr -88Cr -6.02TCr -89Cr -606.18Cr -237.21Cr -2.95TCr -234.76Cr -229.71Cr -10TCr |
| Net Debt | -97Cr -85Cr -79Cr -73Cr -136.92Cr -9.36TCr -138.58Cr -941.57Cr -368.45Cr -4.58TCr -364.65Cr -356.8Cr -16TCr | -88Cr -77Cr -72Cr -66Cr -124.41Cr -8.5TCr -125.91Cr -855.48Cr -334.77Cr -4.17TCr -331.31Cr -324.18Cr -14TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | $73.71 | +2.88% | 6,05,257 |
| 20/26/20 | $71.65 | -3.57% | 24,10,748 |
| 17/26/17 | $74.30 | +4.10% | 37,75,226 |
| 16/26/16 | $71.38 | -0.62% | 25,78,672 |
| 15/26/15 | $71.82 | -0.13% | 18,63,848 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARWR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition